Friday, June 03, 2022
Avivagen Inc. (VIVXF)
A New Vietnamese Distributor
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Distributor. Avivagen’s management recently announced the Company has signed a new distribution agreement with Nong San Viet Co. to support the continued expansion of Avivagen’s OxC-beta feed additive. No details were given on the length of the agreement. We believe that this new distribution, along with the recent China approval and the exclusive distribution agreement with AB Vista, will bring the Company closer to large revenue growth.
Vietnamese Market. Vietnam is home to the largest feed market in Southeast Asia, with total annual feed consumption of over 32 million metric tons in 2020, according to the US Grains Council. The Grain Council reports that Vietnam is a strong growth market for the industry, and is expected to surpass 35 million metric tons within the next few years, with production being dominated by swine, accounting for approximately 38% of total feed, followed by poultry at 21.6%. Swine and poultry are two target markets for Avivagen, so we believe that it bodes well for continued growth for the Company over the next few years….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.